Health Care & Life Sciences » Biotechnology | Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,278.00
52,069.00
148,502.00
147,274.00
314,825.00
477,534
Other Current Assets
448.00
1,524.00
1,222.00
2,495.00
9,487.00
8,246
Total Current Assets
3,726.00
53,593.00
149,724.00
149,769.00
324,312.00
485,780
Net Property, Plant & Equipment
2,366.00
2,023.00
2,114.00
2,420.00
16,571.00
14,981
Total Investments and Advances
80.00
140.00
140.00
50,198.00
15,653.00
114,281
Other Assets
-
-
-
-
184.00
2,601
Total Assets
6,172.00
55,756.00
151,978.00
202,387.00
356,720.00
617,643
Accounts Payable
-
-
-
-
7,177.00
Other Current Liabilities
3,762.00
2,537.00
9,627.00
15,515.00
19,087.00
Total Current Liabilities
3,762.00
2,537.00
9,627.00
15,515.00
26,264.00
Other Liabilities
159.00
384.00
1,556.00
563.00
11,652.00
Total Liabilities
3,921.00
2,921.00
11,183.00
16,078.00
37,916.00
Common Equity (Total)
25,974.00
49,326.00
140,795.00
186,309.00
318,804.00
Total Shareholders' Equity
2,251.00
52,835.00
140,795.00
186,309.00
318,804.00
Total Equity
2,251.00
52,835.00
140,795.00
186,309.00
318,804.00
Liabilities & Shareholders' Equity
6,172.00
55,756.00
151,978.00
202,387.00
356,720.00
Preferred Stock (Carrying Value)
28,225.00
102,161.00
-
-
-

About Global Blood Therapeutics

View Profile
Address
171 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.gbt.com
Updated 07/08/2019
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P.